Drug Type Oligonucleotide |
Synonyms FB 7011, FB7011 |
Target |
Action inhibitors |
Mechanism CFB inhibitors(Complement factor B inhibitors), MASP2 inhibitors(Mannan-binding lectin serine protease 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoinflammatory disease | Preclinical | China | 31 Aug 2024 | |
Glomerulonephritis, IGA | Preclinical | China | 31 Aug 2024 |